Remimazolam
- Generic Name
- Remimazolam
- Brand Names
- Byfavo
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19BrN4O2
- CAS Number
- 308242-62-8
- Unique Ingredient Identifier
- 7V4A8U16MB
- Background
Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites. These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed. Remimazolam was the first "soft" benzodiazepine analog to be developed and was approved for use by the FDA in July 2020 under the brand name Byfavo.
- Indication
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
- Associated Conditions
- Procedural Sedation
Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients
- Conditions
- RemimazolamSedation ComplicationMidazolam
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Peking University
- Target Recruit Count
- 81
- Registration Number
- NCT04602845
- Locations
- 🇨🇳
Peking University Hospital of Stomatology, Beijing, Beijing, China
🇨🇳Zijian Guo, Haidian, Beijing, China
Effect of Remimazolam Use During Perioperative Period on Brain Waves and Postoperative Cognitive Function
- Conditions
- Benzodiazepine
- Interventions
- Drug: control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Yangzhou University
- Target Recruit Count
- 80
- Registration Number
- NCT04601350
- Locations
- 🇨🇳
the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
- Conditions
- Bladder CancerDeliriumBenzodiazepinesCancer RecurrenceSurgery
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT04532606
- Locations
- 🇨🇳
The Sixth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
🇨🇳Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04400201
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04113343
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services, Salt Lake City, Utah, United States
Absolute Oral Bioavailability of Remimazolam
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04113564
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services (EDS), Salt Lake City, Utah, United States
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT04110535
- Locations
- 🇺🇸
PRA Health Sciences Early Development Services, Salt Lake City, Utah, United States
A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- Conditions
- Anesthesia for Elective Surgery Patients
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03921775
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 388
- Registration Number
- NCT03779061
- Locations
- 🇨🇳
Clinical trial Ethnics Committee of Peking Union Medical College Hospital, Beijing, Beijing, China
Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia
- Conditions
- General Anaesthesia
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 150
- Registration Number
- NCT03669484
- Locations
- 🇷🇺
SBHI City Clinical Hospital №1 n.a. N.I. Pirogov, Moscow, Russian Federation
🇷🇺FSBI Central Clinical Hospital and Polyclinic of Adminisatration of the President of the Russian Federation, Moscow, Russian Federation
🇷🇺SBHI Moscow Clinical Research and Practical center of Department of Healthcare of the city of Moscow, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.